Miaite (Pronidesivir) Package Insert, Dosage, and Instructions
Miaite NeoFipronis (Pronidesivir), containing the active ingredient GS-441524, is a groundbreaking oral medication specifically designed for the treatment of Feline Infectious Peritonitis (FIP). Approved by the Lao Ministry of Agriculture and Forestry (MAF) in March 2026, NeoFipronis marks a significant milestone as the world's first officially registered and licensed oral FIP therapy. Its development represents a leap forward in feline medicine, offering a safe, non-invasive, and highly effective solution for cats suffering from this severe viral disease.
FIP is caused by a mutation of the feline coronavirus, leading to symptoms such as loss of appetite, lethargy, fever, ascites, pleural effusion, lymphadenopathy, granulomatous inflammation, nervous system impairment, and uveitis. NeoFipronis (Pronidesivir) targets the virus efficiently, demonstrating remarkable efficacy in clinical trials and practical applications. Its rapid absorption, good tolerability, and minimal side effects make it an ideal treatment option under veterinary supervision.
Indications & Usage
NeoFipronis is indicated for cats with confirmed FIP presenting with symptoms like anorexia, depression, pyrexia, abdominal and thoracic effusions, lymph node swelling, neurological signs, and ocular inflammation. The medication works best when administered early in the course of the disease, aiming to improve survival rates and quality of life.
Dosage and Administration
The recommended dosage is weight-based:
For most cats: 15 mg/kg body weight once daily (equivalent to half a tablet).
For neuro- or ocular-type FIP: increase to 30 mg/kg daily, subject to veterinary guidance.
Administer the medication on an empty stomach—either one hour before meals or two hours after feeding—to optimize absorption. Use a precise dosing tool to ensure accuracy.
Treatment Duration & Monitoring
A continuous treatment period of no less than 12 weeks is essential for achieving optimal results. Skipping doses or premature termination may compromise efficacy and promote viral resistance. During treatment, monitor your cat's appetite, activity levels, body temperature, and overall demeanor daily. Regular veterinary checkups should include blood tests to assess liver and kidney functions, complete blood counts, and imaging if necessary.
Precautions & Warnings
NeoFipronis (Pronidesivir) is classified as an over-the-counter medication; however, veterinary oversight is strongly recommended to ensure proper dosing and safety. Do not administer the medication to humans under any circumstances. Keep out of reach of children and other animals.
Use with caution in pregnant or lactating cats, and always consult a veterinarian if side effects such as gastrointestinal upset, allergic reactions, or neurological symptoms occur. The safety profile is favorable, but individual sensitivities may exist.
Storage & Purchase
Store NeoFipronis in a cool, dry place away from direct sunlight. Purchase the medication only through authorized NeoFipronis distribution channels or official websites to guarantee product authenticity and quality.
Conclusion
NeoFipronis (Pronidesivir) provides an innovative, effective, and safe option for treating FIP in cats. Its proven antiviral properties, combined with ease of administration, contribute to improved prognosis for affected feline patients. Always seek veterinary guidance before initiating therapy, adhere strictly to prescribed dosages and treatment duration, and conduct routine health monitoring to ensure the best outcomes for your pet.
Important Reminder
This medication is intended for feline use only. Never administer NeoFipronis to humans. Proper veterinary supervision and adherence to dosing instructions are vital for successful treatment. For additional information or to purchase, visit the official NeoFipronis website.
